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ABSTRACT
Entry into mitosis is driven by the phosphorylation of thousands of
substrates, under the master control of Cdk1. During entry into
mitosis, Cdk1, in collaboration with MASTL kinase, represses the
activity of the major mitotic protein phosphatases, PP1 and PP2A,
thereby ensuring mitotic substrates remain phosphorylated. For cells
to complete and exit mitosis, these phosphorylation events must be
removed, and hence, phosphatase activity must be reactivated. This
reactivation of phosphatase activity presumably requires the inhibition
of MASTL; however, it is not currently understood what deactivates
MASTL and how this is achieved. In this study, we identified that PP1
is associated with, and capable of partially dephosphorylating and
deactivating, MASTL during mitotic exit. Using mathematical
modelling, we were able to confirm that deactivation of MASTL is
essential for mitotic exit. Furthermore, small decreases in Cdk1
activity during metaphase are sufficient to initiate the reactivation of
PP1, which in turn partially deactivates MASTL to release inhibition of
PP2A and, hence, create a feedback loop. This feedback loop drives
complete deactivation of MASTL, ensuring a strong switch-like
activation of phosphatase activity during mitotic exit.
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INTRODUCTION
The phosphorylation of proteins by cyclin-dependent kinase 1 (Cdk1)
is essential for correct entry into, and progression through, mitosis
(Lindqvist et al., 2009). Cdk1 substrates directly and indirectly ensure
that theDNA is correctly compacted into chromosomes, and positioned
at the centre of the cell through bi-polar attachment to the mitotic
spindle. This process is monitored by the spindle assembly checkpoint
(SAC), which ensures that Cdk1 remains active until all chromosomes
are correctly attached and aligned. Once this is achieved, the SAC
becomes satisfied, releasing inhibition of the E3 ubiquitin ligase
anaphase-promoting complex comprising the cdc20 subunit
(APCcdc20), which targets cyclin B1 for destruction by the
proteasome, inactivating Cdk1 (Wolf et al., 2006). To exit mitosis,
phosphatases reverse the Cdk1-dependent phosphorylation events.
Notably, phosphatases are inhibited by Cdk1 activity, consequently,
inactivating Cdk1 creates a negative-feedback loop that enhances
phosphatase activity, locking the system into irreversible mitotic exit
(Yang and Ferrell, 2013). Differentially oscillating activities of Cdk1
and phosphatase enzymes create a two-state system, which comprises
interphase and mitosis, respectively (Medema and Lindqvist, 2011).
This bistability has been extensively modelled mathematically,
especially with regards to the role of Cdk1 and to protein degradation
duringmitotic exit (López-Avilés et al., 2009; Rattani et al., 2014; Tóth
et al., 2007). Consequently, how regulation of Cdk1 activity ensures the
irreversibility of mitotic exit is now well established.
Recent studies have focussed on how regulating phosphatases
impacts on bistability during mitosis. In yeast, Cdc14 is the primary
phosphatase responsible for counter-balancing Cdk1 activity
(Bouchoux and Uhlmann, 2011); however, in human cells, it does
not appear to play a central role (Mocciaro and Schiebel, 2010).
Consequently, in higher eukaryotes, it is unclear which phosphatase
(s) regulatemitotic exit. In cyclingXenopus extracts, depleting protein
phosphatase-1 (PP1) prevents the dephosphorylation of mitotic
substrates (Wu et al., 2009), whereas Cdk1-mediated
phosphorylation on residue Thr320 of PP1 (which is equivalent to
residues Thr316 and Thr311 in PP1β and PP1γ, respectively; and is
hereafter referred to as Thr320)’ inhibits its activity (Kwon et al.,
1997). However, PP2A combined with the B55 subunit (PP2A-B55)
has also been proposed as themajor phosphatase complex responsible
for counterbalancing Cdk1 activity during mitotic exit in human
(B55α; PPP2R2A) andXenopus (P55δ; PPP2R2D) systems (Schmitz
et al., 2010; Mochida et al., 2009). PP2A-B55 must be inhibited
during mitotic entry to ensure that Cdk1 substrates remain
phosphorylated during mitosis, and it must be subsequently
reactivated upon exit. This mitotic inhibition of PP2A-B55 is under
the control of microtubule-associated serine-threonine-like kinase
(MASTL) (Burgess et al., 2010; Vigneron et al., 2009). MASTL,
originally identified in Drosophila as Greatwall (Gwl) (Bettencourt-
Dias et al., 2004), is phosphorylated (most probably by Cdk1) on
several key residues (Thr194, Thr207, S213 andThr741), followed by
auto-phosphorylation on Ser875 (Blake-Hodek et al., 2012). Active
MASTL then phosphorylates two homologous heat-stable proteins –
α-endosulfine (ENSA) (Ser67) and Arpp19 (Ser62) (Gharbi-Ayachi
et al., 2010; Mochida et al., 2010) –which then bind to the active site
of PP2A-B55, acting as an ‘unfair’ competitive inhibitor (Williams
et al., 2014). To exit mitosis, Cdk1 substrates must be
dephosphorylated; presumably, this requires the deactivation of
MASTL, releasing ENSA-mediated repression of PP2A-B55 activity.
Interestingly, PP2A-B55 has recently been proposed toReceived 31 August 2015; Accepted 8 February 2016
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dephosphorylate MASTL during mitotic exit (Hégarat et al., 2014),
however, because PP2A is inhibited by MASTL, an external trigger
is likely to be required to initiate the deactivation of MASTL
to kick-start PP2A activity. Here, we demonstrate that PP1 is
associated with MASTL during mitotic exit and is capable of
dephosphorylating MASTL, correlating with its deactivation.
Mathematical modelling showed that PP1 is required for triggering
the initial dephosphorylation of MASTL, releasing PP2A inhibition,
which completes MASTL and Cdk1 substrate dephosphorylation. In
summary, our data provide a unifying theory where both PP1 and
PP2A are required for efficient deactivation of MASTL, thereby
establishing a bistable switch that drives mitotic exit.
RESULTS
Biochemical modelling of mitotic exit in human cells
To analyse how MASTL is deactivated during mitotic exit, we
utilised highly enriched cultures of mitotic human (HeLa) cells,
similar to those we and others have used previously (Cundell
et al., 2013; Hégarat et al., 2014; McCloy et al., 2014). Briefly,
thymidine-synchronised cells were released into nocodazole, and
the culture was enriched for prometaphase cells through gentle
mitotic shake-off. The Cdk1 inhibitor RO3306 was then added to
induce synchronised mitotic exit (Fig. 1A). To validate the
synchronised mitotic exit in our model, the APCcdc20 substrates
securin and cyclin B1 were analysed by western blotting. Securin
was rapidly degraded within 5 min, whereas cyclin B1 was slowly
degraded throughout the timecourse, reaching interphase levels at
approximately 60–90 min post Cdk1 inhibition, indicating that
cells had completed mitotic exit by this time (Fig. 1B).
Dephosphorylation of mitotic Cdk1 substrates was analysed
using phosphorylation-specific antibodies for proline-directed
phosphorylated threonine (pThrCdk) and phosphorylated serine
(pSerCdk) sites. Significant dephosphorylation of pThrCdk sites
was observed within 5 min of RO3306 addition, whereas
dephosphorylation of pSerCdk sites occurred with slower linear-
like kinetics (Fig. 1C), similar to cyclin B1 degradation (Fig. 1B).
This preferential dephosphorylation of pThrCdk substrates mirrors
our previous reports on the differential dephosphorylation patterns
that occur during mitotic exit (McCloy et al., 2015). Taken
together, these results indicate that our system is capable of
modelling and temporally separating the early events of mitotic
exit, such as chromosome segregation (securin degradation) and
the preferential dephosphorylation of pThrCdk substrates,
from later events, such as chromosome decondensation and
dephosphorylation of pSerCdk substrates.
Previous reports indicate that MASTL activity is primarily
regulated through phosphorylation (Burgess et al., 2010); however,
degradation of the K71M mutant of MASTL has been reported in
Xenopus oocytes (Yamamoto et al., 2011), and HSP90 depletion
destabilises MASTL (Yamamoto et al., 2014). Therefore, to
determine whether degradation contributes to the regulation of
MASTL during mitotic exit, total protein levels were quantified
either in the presence or absence of the proteasome inhibitor
MG132. Treatment with MG132 successfully blocked cyclin B1
degradation for the length of the timecourse (Fig. 1D); however, no
significant change in MASTL levels in the presence or absence of
MG132 were observed, indicating that degradation does not play a
role in regulating MASTL during mitotic exit (Fig. 1D). In contrast,
potential dephosphorylation of MASTL, as indicated by a band
shift, was noticeable within 10 min, independent of proteasome
inhibition. This dephosphorylation of MASTL was also observed in
MCF10A and MDA-MB-157 human cell lines (Fig. 1E), indicating
that dephosphorylation is likely to be the primary mode of
regulating MASTL during mitotic exit in human cells.
Therefore, we next analysed the kinetics of MASTL
dephosphorylation and kinase activity. Within 5 min of triggering
mitotic exit, a decrease in the mobility of MASTL was observed,
which continued step-wise until 90 min, when migration of the
protein matched that in interphase cells, indicating complete
dephosphorylation (Fig. 1F). Surprisingly, despite this step-wise
dephosphorylation, significant loss of kinase activity, as determined
by in vitro kinase assays, was observed within 5 min of triggering
mitotic exit (Fig. 1F). In contrast, Cdk1–cyclin-B1 in vitro kinase
activity showed a slow linear decline throughout the timecourse
(Fig. 1F), which correlated with the degradation of cyclin B1
(Fig. 1B). Taken together, these results suggest that a subset of
key phosphorylation sites within MASTL are initially
dephosphorylated, causing a small increase in mobility, as detected
byobserving a band shift, and a significant decrease in kinase activity.
Analysis of MASTL phosphorylation sites during mitotic exit
Human MASTL has 50 reported phosphorylation sites in the
PhosphoSitePlus database (http://www.phosphosite.org/); however,
in Xenopus, only Thr194, Thr207, Ser213, Thr741 and Ser885
appear to be crucial for kinase activity (Blake-Hodek et al., 2012). To
analyse the dephosphorylation of humanMASTL during mitotic exit,
we mined our recent publication of the global phosphoproteomic
mapping of early mitotic exit for MASTL phosphosites (McCloy
et al., 2015). This large dataset identified 18 mitotic phosphorylation
sites on MASTL, and all exhibited quantitative log2 scores, with the
exception of Ser875, which owing to the cleavage site of trypsin, did
not contain any heavy isotope residues after stable isotope labelling
(SILAC) (Fig. 2A). The ratios for the majority of sites showed a
fourfold decrease (log2 scores <−2, blue), indicating that they were
rapidly dephosphorylated during earlymitotic exit, with SILAC ratios
for Ser222, Ser452, Ser660 and Ser668 all statistically significant
(adjusted P-values <0.05). The Thr207 site was also rapidly
dephosphorylated; however, SILAC ratios were only found in two
of the three biological replicates, limiting its significance (P-value
<0.06).
To analyse the dephosphorylation on MASTL in greater detail,
we immunoprecipitated endogenous MASTL using a polyclonal
antibody raised against the full-length protein from synchronised
mitotic extracts (Fig. 2B). These were then probed with a
phosphorylation-specific antibody against the Ser875 auto-
phosphorylation site in MASTL (Vigneron et al., 2011).
Surprisingly, phosphorylation on Ser875 remained stable
throughout mitotic exit, suggesting that this site, although crucial
for activity, was not involved in regulating the deactivation of
MASTL in our system (Fig. 2B). We therefore turned our attention
to the other sites in MASTL that are crucial for activity (Thr194,
Thr207, Ser213 and Thr741). Unfortunately, we were unable to
produce phosphorylation-specific antibodies for these sites.
However, all the threonine sites are proline directed and,
therefore, potentially phosphorylated by Cdk1. In support of this
notion, both the Thr194 and Thr207 sites can be phosphorylated by
Cdk1 in vitro (Blake-Hodek et al., 2012). Given this information,
we reasoned that the antibody recognising pThrCdk substrates could
serve as a surrogate marker for these sites. Probing MASTL
immunoprecipitations with the antibody recognising pThrCdk sites
revealed a rapid (∼50%) reduction in signal within 5 min of
triggering mitotic exit, with complete loss by 60 min (Fig. 2B). In
contrast, precipitation of the retinoblastoma protein (Rb; also known
as RB1), a substrate we have previously identified to be stably
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Fig. 1. Mitotic exit within human cells is accompanied by rapid dephosphorylation and deactivation of MASTL. (A) Schematic of the method used to
generate synchronisedmitotic exit in human cells. (B,C) HeLa cells synchronised as shown in Awere lysed and analysed by western blotting for securin, cyclin B1,
pThrCdk substrates, pSerCdk substrates and β-actin (loading). Quantification was performed, and the intensity is expressed relative to the protein level at 0 min.
Mean+ s.e.m. for n=3 values, (one-way ANOVA). I, interphase; n.s., not significant; RO, RO3306. (D) HeLa cells synchronised as per Awere treated with 25 μMof
the proteasome inhibitor MG-132 (RO+MG) or without (+RO) for 15 min prior to RO3306 addition. Lysates were blotted for MASTL, where phosphorylatedMASTL
(pMASTL) and dephosphorylated MASTL (MASTL) are indicated by band shift. Cyclin B1 and Ku-86 (loading, also known as XRCC5) were also probed.
Quantification was performed, and the intensity is expressed relative to the protein level at 0 min. Mean+s.e.m. for n=3 (two-way ANOVA). (E) HeLa (cervical),
MDA-MB-157 (breast) and MCF-10A (breast) epithelial cells were treated as shown in A. Lysates were immunoblotted for MASTL, cyclin B1 and Ku-86 (loading).
(F) HeLa cells were synchronised as described in A. Cyclin B1 and MASTL were immunoprecipitated (IP) from clear lysates (IN) and then immunoblotted,
or assayed using a GloMax Luminescence Kinase Assay kit. Quantification was performed, and MASTL and Cdk1 activity are expressed relative to that at
0 min, corrected to interphase. Mean+s.e.m., n=3 (one-way ANOVA). Grey shading indicates significant points; *P<0.05; **P <0.01; ****P <0.0001; n.s., not
significant. Cdk1/cyclin B1, Cdk1–cyclin-B1 complex.
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phosphorylated at pThrCdk sites during mitotic exit (McCloy et al.,
2015), showed consistent levels of staining of pThrCdk residues
throughout the timecourse. Notably, phosphorylation of the Ser780
site on Rb was gradually removed during mitosis (Fig. 2C). Control
immunoprecipitations using an antibody against rabbit IgG did not
show any cross-reactive staining for pThrCdk sites (Fig. 2D). Taken
Fig. 2. Cdk1 phosphorylation at threonine residues on MASTL are removed during early mitotic exit. (A) Summary of MASTL phosphorylation changes
during early mitotic exit, as determined by SILAC mass spectrometry analysis. Sites crucial for kinase activity (green), proline-directed potential Cdk1
phosphorylation sites (red) and significantly dephosphorylated sites (*) are shown. Kin., kinase. (B) MASTL was immunoprecipitated (α-MASTL) from extracts
as described in Fig. 1B, immunoblotted for total MASTL levels, pThrCdk substrates (pThrCdk MASTL) and MASTL that had been phosphorylated on Ser875
(pS875 MASTL). Quantification was performed, and the intensity is expressed relative to the protein level at 0 min, normalised to IgG loading. n=3; ***P<0.001;
(one-way ANOVA). (C) Similar to the experiment shown in B, retinoblastoma protein (Rb) was immunoprecipitated (IP: α-Rb), and precipitates blotted for total Rb
or pThrCdk substrates (pThrCdk Rb); total lysates were blotted for Rb phosphorylated on Ser780 (pS780 Rb) and β-actin (loading). (D) IgG precipitation (α-IgG)
controls corresponding to B and C. (E) PLA using primary antibody pairs against MASTL and pThrCdk substrates. Red dots, interaction foci; blue, nuclei. Data are
mean+s.e.m., for a minimum of five cells, n=2. Results in prometaphase and anaphase cells were compared (red bars); ***P<0.001 (two-way ANOVA). Scale
bars: 10 μm. I, interphase; P, prophase; Pm, prometaphase; M, metaphase; A, anaphase; T, telophase.
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together, these results suggest that the antibody recognising
pThrCdk substrates is able to specifically identify phosphorylated
sites within MASTL.
To further validate these findings under normal mitotic exit
conditions, we utilised in situ proximity ligation assays (PLAs),
which detect the colocalisation of two proteins within 40 nm
(Rogers et al., 2015a). Negative control PLA assays using
antibodies recognising pThrCdk substrates or MASTL in
combination with IgG showed very few interactions, consistent
with background levels (Fig. S1A,B). Combination of antibodies
recognising MASTL and pThrCdk substrates showed a significant
increase over background levels, with the number of interactions
increasing as cells entered mitosis, peaking during prometaphase
and then declining significantly as cells entered anaphase (Fig. 2E).
This dephosphorylation trend paralleled the loss observed by
western blotting MASTL immunoprecipitations (Fig. 2B) and
correlated with the kinetics of deactivation of kinase activity
(Fig. 1F). Hence, the fact that MASTL dephosphorylation occurred
concurrently with kinase inactivation implies that these events
could be correlated.
Identification of the phosphatase responsible for
deactivating MASTL during mitotic exit
The above results indicate that MASTL activity is regulated by rapid
dephosphorylation on key sites during early mitotic exit. To identify
the phosphatase responsible for triggering this initial partial
dephosphorylation of MASTL, we precipitated MASTL from
cells that had been subjected to stable isotope labelling using amino
acids in cell culture (SILAC) and then analysed bound proteins by
performing quantitative mass spectrometry. Briefly, cells were
cultured for 6–7 doublings in the presence of ‘heavy’ or ‘light’
amino acids, as described previously (McCloy et al., 2015). Cells
were then synchronised as per Fig. 1A, where ‘light’ samples
remained arrested in prometaphase and ‘heavy’ cultures were treated
with RO3306 for 20 min to induce mitotic exit. Endogenous
MASTL was immunoprecipitated from both cultures, mixed 1:1,
separated by gel electrophoresis, digested in-gel and analysed by
performing liquid chromatography tandem mass spectrometry (LC-
MS/MS) analysis (Fig. 3A). Importantly, MASTL was highly
enriched, with good sequence coverage (44.3%) and significant
peptide identification confidence (posterior error probability
2.43×10−176), providing an internal positive control (Fig. 3B).
After filtering for contaminants, a total of 753 unique proteins were
identified and quantified by performingmass spectrometry allowing
for a 1% false discovery rate (Table S1). Analysis of this dataset
revealed eight phosphatase proteins that could potentially interact
with MASTL during mitotic exit (Fig. 3B). The list contained the
scaffolding A (also known as PPP2R1A) and regulatory B55α
subunit of PP2A (PPP2R2A), the regulatory subunit myosin
phosphatase MYPT1 (PPP1R12A) and myosin phosphatase Rho-
interacting protein (MPRIP), along with the catalytic α, β and γ
subunits of PP1 (also known as PPP1CA, PPP1CB and PPP1CC,
respectively). Although all three PP1 isoforms were ‘detected’, the
majority (11 out of 14) of peptides identified were not isoform
specific. The positive SILAC ratios for PP1γ, MYPT1, MPRIP and
PP2A-B55 suggest increased association with MASTL during
mitotic exit (log2 ∼0.3 to 0.6), whereas PP1α and PP1β association
with MASTL is slightly reduced. However, these values were all
well below the standard twofold-change threshold (log2 > 1)
normally required for relevance. In summary, the higher
confidence identification of multiple PP1-family members
suggests that PP1 is the potential MASTL phosphatase.
To confirm the above interactions, additional co-
immunoprecipitation and western blot analyses were performed.
Immunoprecipitation of endogenous MASTL from prometaphase
and early mitotic exit samples showed that there was a strong
interactionwith the catalytic PP1β subunit,which notably increased in
the earlymitotic exit (+RO) sample (Fig. S1C, IP1). Further depletion
ofMASTL from the same extracts failed to recapitulate any noticeable
association with PP1β (Fig. S1C, IP2). In addition, MASTL was
detected, albeit weakly, in the reverse PP1β immunoprecipitations
(Fig. S1D). However, depletion of extracts with a control rabbit IgG
antibody was also able to weakly co-precipitate PP1β during the
mitotic exit sample (Fig. S1C). The presence of IgG prevented the
analysis of the PP2A scaffolding A and B55 subunits in MASTL
immunoprecipitations; therefore, we probed for the catalytic subunit
of PP2A. However, no association was observed, suggesting that
PP2A is not strongly associatedwithMASTLduring earlymitotic exit
events. Taken together, although MASTL and PP1β appear to be
associated during mitotic exit, the non-specificity observed with IgG
prevents us from concluding this conclusively.
Therefore, to overcome issues associated with non-specific IgG
precipitation of PP1, and to validate the interactions under normal
mitotic progression, we utilised PLA assays. To ensure specificity of
the antibodies used for PLA, small interfering (si)RNA knockdown of
MASTL, PP1β (PPP1CB), the catalytic subunit of PP2A (PPP2CA)
and the B55 subunit of PP2A (PPP2R2A) were performed, followed
by immunofluorescence analysis. Knockdown of each protein clearly
reduced the signal observed in immunofluorescence analysis
compared to that observed with the non-targeting controls,
indicating that the antibodies specifically recognised their target
antigens (Fig. S2A–F). As a positive control for PLA, the proximity of
cyclin B1 and Cdk1 was analysed. The number of interactions
between cyclin B1 and Cdk1 increased as cells entered mitosis,
peaking at prometaphase, before significantly declining as cells
entered anaphase and telophase, corresponding with the reported
cyclic production and destruction of cyclin B1 in HeLa cells (Fig. 3C)
(Chang et al., 2003).An additional control usingMASTLmouse (Mo)
combined with MASTL rabbit (Rb) antibodies was also performed.
The number of interactions between MASTL(Mo) and MASTL(Rb)
decreased significantly during prometaphase compared to interphase,
and then rose again as cells exited mitosis (Fig. S3A). This change is
likely to be due to the reduced ability of the antibodies to completely
detect phosphorylated forms of MASTL. Finally, no significant
association between IgG and MASTL, and between IgG and PP1β
were observed (Figs S1A and S3B), indicating that the non-specific
interaction between IgG and PP1 was restricted to the
immunoprecipitation analyses. Importantly, PP1β–MASTL PLA
assays showed positive interactions that increased significantly as
cells progressed from interphase into mitosis, peaking at anaphase,
before decreasing in telophase (Fig. 3D). The increase observed during
anaphase, although significant, could be due to better antigen retrieval,
as noted by the corresponding increase inMASTL(Mo)–MASTL(Rb)
interactions (Fig. S3A). In contrast, no significant associations
between the catalytic or the B55 subunit of PP2A and MASTL were
observed by performing PLA (Fig. 3E; Fig. S3C), indicating that
PP2A-B55 is not closely associated with MASTL during mitosis.
Taken together, these data indicate that PP1 is associatedwithMASTL
during the early phases of mitotic exit and, hence, is potentially
capable of triggering the dephosphorylation of MASTL.
In vitro and in vivo dephosphorylation of MASTL by PP1
The above data suggest that PP1 has the potential to deactivate
MASTL, possibly by dephosphorylating crucial Thr194, Thr207
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and Thr741 pThrCdk sites during early mitotic exit (Fig. 2A).
For this model to hold true, it would require rapid reactivation of
PP1 during early mitotic exit, to allow subsequent
dephosphorylation of MASTL. To test this, we analysed PP1
auto-dephosphorylation of its inhibitory Thr320 site (Wu et al.,
2009) in our synchronised mitotic exit system. Significant loss of
Thr320 was observed within 5 min of triggering mitotic exit,
with complete dephosphorylation of Thr320 occurring within
60 min (Fig. 4A). Accordingly, rapid dephosphorylation of
histone H3 on Thr3, a known PP1 substrate (Qian et al.,
2011), was also observed within 5 min (Fig. 4A). Taken together,
these data indicate that PP1 is activated rapidly upon triggering
Fig. 3. MASTL binds to PP1 during mitotic exit. (A) Schematic of SILAC labelling, co-immunoprecipitations and LC-MS/MS analysis of endogenous MASTL.
(B) Summary table of MaxQuant analysis of the results obtained using the protocol outlined in A showing the phosphatases identified as being associated
with MASTL, posterior error probability (PEP), and log2 heavy:light ratios (Log2). Seq. cov, sequence coverage. Noc, nocodazole; RO, RO3306.
(C–E) Representative maximum projections (C only) and rendered 3D images of the PLA assay using primary antibody pairs against (C) Cdk1 and cyclin
B1 (control), (D) MASTL and PP1β, and (E) MASTL and the catalytic subunit of PP2A, PP2A/C (PPP2CA). Individual PLA dots (red) were quantified using the
Imaris dot counter across interphase (I), prophase (P), prometaphase (Pm), metaphase (M), anaphase (A) and telophase (T). The number of foci in prometaphase
and anaphase cells were compared (red bars) for n>5 cells across two replicates. Blue, nuclei. ****P<0.00001; n.s., not significant (two-way ANOVA). Data are
mean+s.e.m. Scale bars: 10 μm. n.s., not significant.
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of mitotic exit with RO3306, with the timing correlating with the
dephosphorylation of MASTL.
To examine whether PP1 can dephosphorylate MASTL, we
performed in vitro phosphatase assays on precipitated MASTL. To
ensure maximum MASTL phosphorylation, cells were treated for
60 min with the PP1 and PP2A inhibitor okadaic acid prior to
harvesting. Precipitated MASTL was then treated without (control)
or with purified PP1α, PP1β or λ phosphatase for 15, 30, 45 or
60 min. MASTL remained phosphorylated in control samples
throughout the timecourse (Fig. 4B; Fig. S3D), whereas treatment
with λ phosphatase increased MASTL mobility within 15 min and
almost completely dephosphorylated MASTL at 60 min (Fig. 4B;
Fig. S3E). Similarly, treatment with PP1α (Fig. 4B) and PP1β
(Fig. S3D) produced a small but noticeable increase in MASTL
mobility within 15 min; however, this only slightly increased over
the remainder of the timecourse. This suggests that PP1 specifically
targets a subset of the phosphorylated residues on MASTL. In
support of this notion, treatment with PP1α almost completely
removed phosphorylation of pThrCdk sites within 15 min, whereas
phosphorylation of MASTL on Ser875 was only partially reduced
after 60 min of treatment with PP1α. Notably, λ phosphatase
efficiently removed both pThrCdk site and Ser875 phosphorylation
within 15 min, with near-complete dephosphorylation observed
after 60 min (Fig. 4B; Fig. S3E).
The above data indicate that PP1α and PP1β can partially
dephosphorylate MASTL in vitro. To analyse this in vivo, HeLa
Fig. 4. PP1 is rapidly activated during mitotic exit and
capable of partially dephosphorylating MASTL
in vitro. (A) Lysates that had been treated as per Fig. 1A
were blotted for PP1 that had been phosphorylated on
Thr320 (pThr320-PP1), total PP1β, the PP1 substrate
histone H3 phosphorylated on Thr3 (pThr3-H3) and
β-actin (loading). Quantification was performed, and the
intensity is expressed relative to the protein level at 0 min.
Mean+s.e.m. for n=3. ****P<0.001 (one-way ANOVA).
RO, RO3306. (B) MASTL immunoprecipitated from
mitotic HeLa extracts, treated with okadaic acid and
incubated with recombinant PP1α or λ phosphatase
(Lambda PPase) or without (control) for the indicated
timepoints. Samples were analysed by western blotting.
Phosphorylation of MASTL was assessed by band shift
and phosphorylation of pThrCdk sites. (C) HeLa cells that
had been transfected with 50 nM of siRNA against PP1α,
PP1β or a non-targeting control (NT) for 24 h. Cells were
then treated as described in Fig. 1A. Dephosphorylation
of MASTL was analysed by band shift, and PP1 activity
was measured by pThr3-H3 dephosphorylation. Values
indicate the percentage of PP1α and PP1β remaining
after knockdown relative to control (%Rel. Exp.).
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cells were transfected with siRNAs against PP1α or PP1β, and the
kinetics of MASTL dephosphorylation was examined using our
synchronised mitotic exit model (Fig. 1A). Knockdown of PP1γ,
and complete knockdown of PP1α or PP1β caused significant
toxicity and inhibited mitotic entry (data not shown). However,
sufficient numbers of mitotic cells were obtained with partial (∼20–
50%) depletion of PP1α or PP1β. Unfortunately, triggering mitotic
exit with 10 µM of RO3306 in cells that had been partially depleted
of PP1α or PP1β had no clear effect on MASTL dephosphorylation
kinetics. The lack of in vivo effects could be due to the potential
redundancy between PP1 isoforms, evidenced by both PP1α and
PP1β dephosphorylating MASTL in vitro. In support, in the
sections below, we employed mathematical modelling of mitotic
exit to guide our experiments and were subsequently able to observe
direct effects of PP1 co-knockdown on MASTL phosphorylation
in vivo.
Development of a mathematical model of phosphatase
reactivation during mitotic exit
Our data above implicate PP1 as the phosphatase responsible for
triggering deactivation of MASTL during mitotic exit. We were
unable to confirm this result in vivo, most likely because of
limitations with sensitivity and toxicity of PP1 knockdown in our
mitotic exit system. Therefore, we developed a computational model
Fig. 5. The bistability of mitotic exit can be modelled using observed experimental parameters. (A) A model of the bistable phosphatase activity during
mitosis, with repression (red shading) during metaphase and activation (blue shading) separated by the bistable switch (green shading). (B) Schematic of
the mathematical model, with dephosphorylation of MASTL by PP1 (bold red line) and feedback from PP2A (dotted red line) onto either PP1 (a; model a) or
MASTL (b; model b). (C,D) Optimized mathematical model where model a is fitted to training data from 50 independent parameter estimation runs (C). Best fit
(black line) depicts 91.1% Cdk1 inhibition. (D) Model b – 60% of the simulations run accurately fit experimental data.
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based on our empirical data to delineate the minimal requirements
needed for triggering PP1 dephosphorylation of MASTL and
mitotic exit. A central component for mitotic exit is the presence of a
bistable switch (green shading, Fig. 5), where the presence of
feedback loop(s) triggers the transition between two stable states,
mitosis (on, red shading) and interphase (off, blue shading)
(Verdugo et al., 2013) (Fig. 5A). The core of our model (Fig. 5B;
see Fig. S3F for a reaction kinetic scheme) is based on established
models of Cdk1, MASTL, ENSA and PP2A activity. Specifically,
our model comprises two feed-forward loops (black lines) from
Cdk1, the first suppresses the phosphatase activities of PP1 by
phosphorylation of Thr320 (Wu et al., 2009), and the second
suppresses PP2A through MASTL phosphorylation of ENSA
(Gharbi-Ayachi et al., 2010). Two feedback loops (red lines) were
also incorporated – a positive-feedback loop from PP1 to itself and a
double negative-feedback loop through inhibition of MASTL and
re-activation of PP2A, as indicated by our data (Figs 2 and 3). In
the positive loop, PP1 can activate itself through auto-
dephosphorylation of its inhibitory Thr320 residue, which is
under the control of Cdk1 (Wu et al., 2009). The double negative-
feedback loop is initiated by the deactivation of MASTL by PP1,
which in turn releases PP2A inhibition (Fig. 5B). To close this
double feedback loop, we created two alternative models (Fig. S3F).
The first model (Fig. S3Fa, model a) was based on the direct and/or
indirect reactivation of PP1 by PP2A through regulation of MYPT1
(Lontay et al., 2005), and on dephosphorylation of inhibitors
inhibitor 1 (I-1; also known as PPP1R1A) and Darpp32 (also known
as PPP1R1B) (El-Armouche et al., 2006; Wu et al., 2009). In the
second model (Fig. S3Fb, model b), PP2A directly feeds back onto
MASTL and is responsible for the removal of additional phosphate
moieties added by Cdk1 and for the inhibition of MASTL activity
(Hégarat et al., 2014). All equations, reaction values and estimated
parameter values are listed in Tables S2–S6.
To train these models, we utilised the biological data generated
from our highly synchronised mitotic exit system detailed above
(Figs 1A–F,2B,4A) – combined with the reported published
abundance for each protein in HeLa cells from the MOPED
database (https://www.proteinspire.org; Kolker et al., 2012) – and
the reported Km and Kcat values for the dephosphorylation of
ENSA by PP2A-B55 (Williams et al., 2014). The remaining
dephosphorylation rates were uncertain and, thus, estimated using
the model in Fig. S3Fa and adaptive simulated annealing, a
method for global parameter estimation (Ingber, 1989). To assess
the associated uncertainty, a Monte-Carlo-based approach was
used where the initial parameters were randomly changed 50
times and the model refitted to the experimental data (Hengl
et al., 2007; Maiwald and Timmer, 2008). We then analysed
parameter correlations and variability of the simulated
predictions, and although the exact parameter values were not
uniquely identifiable, their estimates occupied highly structured
regions in the parameter space resulting in parameter correlations
(Fig. S3G).
For the model in Fig. S3Fa, all 50 estimated models (light grey
lines), and in particular the best-fitting model (solid back line),
closely matched our experimental data (red dots) for the kinetics of
PP1 inhibition (Thr320 dephosphorylation), MASTL kinase
activity and the dephosphorylation of global pThrCdk sites – a
readout of PP2A reactivation and mitotic exit (Fig. 5C). Using the
same parameter estimates, the model shown in Fig. S3Fb was also
able to closely match our experimental data in 60% of the
simulations (Fig. 5D). This indicates that the differences between
the two models are not crucial for explaining these data and,
therefore, for simplicity, we choose the model shown in Fig. S3Fa
for further analysis.
Validation of the model
One limitation of the above simulations and our biological system is
that they relied on instantaneous inhibition of Cdk1. Therefore, our
first simulation was to test whether bistable switch-like dynamics
would be maintained if Cdk1 activity declined gradually, similar to
the normal degradation of cyclin B1. Simulating the model with two
different decay rates of Cdk1 activity delayed the onset of mitotic
exit (Fig. 6A). Importantly, this delay did not alter the switch-like
behaviour with regards to PP1 inhibition, deactivation of MASTL
and subsequent dephosphorylation of pThrCdk substrates, which all
occurred with similar kinetics to those observed with instantaneous
Cdk1 inhibition. This indicates that Cdk1 activity determines the
timing of mitotic exit, and once Cdk1 activity drops below a certain
threshold, the bistable phosphatase switch is triggered and mitotic
exit occurs. Therefore, our method of instantaneous Cdk1 inhibition
is a useful method for modelling mitotic exit.
Next, we utilised the model to determine the threshold of Cdk1
activity that triggers the bistable switch and mitotic exit.
Surprisingly, the model identified a clear bistable threshold, with
90% or greater inhibition of Cdk1 required to trigger PP1 activation,
and MASTL and pThrCdk substrate dephosphorylation (Fig. 6B).
To validate this experimentally, increasing doses of RO3306 were
added to Nocodazole-arrested cells for 30 min. No significant effect
on the dephosphorylation of MASTL (as determined by band shift)
was observed below concentrations of 1 µM of RO3306 (Fig. 6C).
A small increase inMASTLmobility and dephosphorylation of PP1
on residue Thr320 was observed at 3 µM, which became clear and
significant at 5 µM. Notably, a dose of 5 µM has been reported to
inhibit up to 90% of cyclin-B–Cdk1 activity (Vassilev et al., 2006),
matching the predictions made by our model.
Based on these data, we hypothesised that sub-optimal doses of
RO3306 at the switching threshold for Cdk1 might allow subtle
changes in MASTL dephosphorylation to be observed with siRNA
depletion of PP1. To test this, we repeated the partial knockdown of
PP1α and PP1β and then treated cells with 1–5 µM of RO3306 for
30 min. No clear effect was seen when PP1α or PP1βwere depleted
individually (Fig. S4A); however, partial co-depletion of PP1α and
PP1β produced a small but noticeable increase in the slower-
migrating form of MASTL at both 1 and 3 µM (Fig. 6D). This
corresponded with a slight increase in the amount of histone H3 that
had was phosphorylated at Thr3, indicating that PP1 was partially
inhibited. Taken together, these data suggest that PP1 is capable of
directly regulating the dephosphorylation of MASTL during mitotic
exit. Furthermore, there is some redundancy between PP1α and
PP1β, which is likely to explain why we failed to observe any effect
in single-knockdown experiments.
To further validate PP1 dephosphorylation of MASTL in vivo,
we employed a novel peptide activator (PDP3) of PP1 (Chatterjee
et al., 2012). Treatment of a population of prometaphase-arrested
cells with PDP3 induced a small (∼20%) decrease in
phosphorylation at Thr320 on PP1. This corresponded with
significant dephosphorylation on Thr3 of histone H3, indicating
that PP1 is reactivated by the peptide (Fig. 6E). To estimate the level
of MASTL dephosphorylation, we compared the ratio between the
phosphorylated (Fig. 6E, upper bands, green) and dephosphorylated
(Fig. 6E, lower bands, red) migrating bands. The levels of MASTL
dephosphorylation closely matched those of dephosphorylation at
Thr320 on PP1, with treatment with PDP3 alone inducing a ∼20%
increase in MASTL mobility. Interestingly, this partial ∼20%
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Fig. 6. A threshold of Cdk1 activity and PP1 are required to trigger the mitotic exit switch. (A) Rate of Cdk1 inhibition from model a was changed to
incorporate two different linear decay rates (blue lines), and subsequent effects on PP1 inhibition, MASTL activity and pThrCdk substrate dephosphorylation
modelled. (B) Inhibition of Cdk1 was varied from 5 to 100% in 5% increments using model a. (C) Validation of Cdk1 bistability threshold. Whole-cell lysates
that had been treated with RO3306 (RO) for 15 min were probed by western blotting for total PP1β, PP1 phosphorylated at Thr320 (pThr320-PP1) and MASTL.
Shown are representative blots, and quantification was performed – the intensity is expressed relative to the protein level at time 0min. Mean+s.e.m., n=3. MASTL
activity was estimated by quantifying the ratio of phosphorylatedMASTL (pMASTL) (green lines) toMASTL (red lines) (pMASTL:MASTL); bistability is highlighted
(grey shading). ****P<0.0001 (ordinary one-way ANOVA). (D) HeLa cells that had been co-depleted of PP1α (25 nM) and PP1β (25 nM) (combo) or with non-
targeting (NT, control) siRNAwere synchronised, as per Fig. 1A, treatedwith increasing concentrations of RO3306 for 30 min and assessed bywestern blotting for
knockdown efficiency, dephosphorylation of MASTL (band shift) and of PP1 substrate histone H3 (pThr3-H3). Values represent the amount of PP1α and
PP1β remaining, relative to that with control treatments (%Rel. Exp.). n=2. (E) HeLa cells were synchronised as described in Fig. 1A but treated with the
PP1-activating peptide PDP3 (40 μM, P) or vehicle (V, Veh) control for 3 h prior to harvest. Samples were treated with (+RO) or without 3 µM RO3306 for 30 min.
Lysates were analysed by western blotting and quantified relative to vehicle (far left lane), for pThr320-PP1, total PP1β, MASTL, pThr3-H3 and β-actin [see
Fig. S4B for PRC1 phosphorylated at Thr481 (pThr481-PRC1) and pThrCdk substrates (pThrCdk Subs)]; n=2.
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activation of PP1 and inhibition of MASTL did not trigger mitotic
exit, with PP2A substrates (pThrCdk sites and PRC1 at Thr481)
remaining phosphorylated (Fig. 6E; Fig. S4B). Next, we
hypothesised that combination of PDP3 with partial inhibition of
Cdk1 just below the bistability threshold might trigger mitotic exit.
Addition of 3 µM RO3306 reduced phosphorylation of Thr320 on
PP1 by∼50% that, when combined with PDP3, reduced to∼75% of
control levels and resulted in a near-complete dephosphorylation of
histone H3 at Thr3. MASTL dephosphorylation coincided with PP1
reactivation, with treatment with RO3306 increasing mobility by
∼50%, whereas PDP3 in combination with RO3306 reduced
phosphorylation by ∼75% (Fig. 6E). Surprisingly, although
addition of 3 µM RO3306 did increase the dephosphorylation of
pThrCdk sites and PRC1 (at Thr481) more than PDP3 alone, the
combination of PDP3 and RO3306 did not significantly increase
dephosphorylation further (Fig. 6E; Fig. S4B), indicating that PP2A
remained partially inhibited under these conditions. These data were
used to update all the parameter estimations in our mathematical
model (Fig. S4C). Importantly, introduction of partial (20–40%)
activation of PP1 and subsequent MASTL deactivation
corresponded with a similar partial dephosphorylation of
pThrCdk substrates but did not trigger the bistable mitotic exit
switch (Fig. S4D). Furthermore, this revised model (a rev) was still
able to accurately model our experimental data based on rapid (90%)
Cdk1 inhibition (Fig. S4E). Notably, previous reports in Xenopus
cell-free extracts have indicated that as little as ∼30% of MASTL
activity is sufficient for maintaining phosphorylation of mitotic
substrates (Blake-Hodek et al., 2012; Vigneron et al., 2011), which
is likely to explain why partial dephosphorylation and deactivation
of MASTL by PP1 is insufficient to drive mitotic exit by itself.
MASTL deactivation is essential formitotic exit and requires
both PP1 and PP2A
An important hypothesis of this work is that MASTL must be
deactivated to permit mitotic exit. In support, we have previously
shown in Xenopus extracts that the mitotic state is lost upon
depletion of MASTL, even when Cdk activity is maintained
(Vigneron et al., 2009). However, to date, no one has been able to
produce a constitutively active form of MASTL with which to
validate this hypothesis. Therefore, we introduced a constitutively
active form of MASTL into our model. Interestingly, this
completely prevented exit and bistability (Fig. 7A). Similarly,
complete removal of the auto-dephosphorylation loop on PP1 was
sufficient to prevent the bistable switch at the estimated level of
Cdk1 inhibitor effectiveness (dCdk1=0.911) (Fig. 7B, red line). To
examine the dynamics of PP1-mediated MASTL deactivation in
more detail, we simulated the effects on MASTL deactivation upon
increasing levels of PP1 inhibition. Increasing inhibition of PP1
from 30 to 70% caused incomplete deactivation of MASTL and
dephosphorylation of pThrCdk substrates without significantly
affecting the shape of the response (Fig. 7B,C). However, to
completely prevent MASTL deactivation and to block mitotic exit,
>90% PP1 inhibition was required (Fig. 7A,B, light green line).
Further, the response to PP1 inhibition was gradual, resembling a
linear rather than an ultrasensitive switch-like curve; hence, there is
no pronounced threshold at which mitotic exit is prevented, further
explaining why partial siRNA-mediated depletion or reactivation
of PP1 with PDP3 only had a small effect on MASTL
dephosphorylation. Therefore, we next examined the impact that
PP2A has on MASTL deactivation and bistability in our model. In
contrast to that of PP1, the PP2A response was highly nonlinear and
switch-like. Partial inhibition of PP2A (30%; Fig. 7, dark blue line)
significantly delayed the kinetics of mitotic exit, and the bistable
switch was completely abolished at 50% inhibition of PP2A (light
blue line) (Fig. 7D,E). This non-linear switch-like response
indicates that the feedback loop from PP2A to PP1 (and/or
MASTL) is crucial for generating the required ultrasensitivity. To
validate this prediction, we took advantage of the 10–100-fold
differential selectivity of okadaic acid for PP2A over PP1 (Swingle
et al., 2007), with doses below 1 µM reported to be specific for
PP2A in human cell lines (Favre et al., 1997). A HeLa cell culture
that had been enriched for prometaphase cells was exposed to
increasing doses of okadaic acid (0–2000 nM) prior to triggering
mitotic exit with RO3306. Based on our model, mitotic exit and
MASTL dephosphorylation should be rescued when >50%
inhibition of PP2A is achieved. In support of this hypothesis,
rescue of MASTL and global pThrCdk phosphorylation was
observed at 50–100 nM, with near-complete rescue observed at
500 nM of okadaic acid (Fig. 7E). In contrast, a dose of 1–2000 nM
was required to rescue the auto-dephosphorylation of PP1 on
Thr320 and to significantly increase the levels of phosphorylation of
histone H3 on Thr3, indicating substantial PP1 inhibition.
Interestingly, these high doses were able to further increase the
band shift observed for MASTL, further supporting the notion of a
role for PP1 in triggering a partial dephosphorylation of MASTL.
To test the importance of PP1 for MASTL dephosphorylation, we
created a final alternative model (model c), where the negative
feedback from PP1 to MASTL was removed, but feedback from
PP2A to MASTL and PP1 remained (Fig. 7G). Simulations with
this alternative model (black lines, Fig. S4F) closely matched the
findings of our experimental data (blue dashed lines) for the
dephosphorylation of PP1 observed upon inhibition of Cdk1.
However, it was unable to model the dephosphorylation of MASTL
or pThrCdk substrates, the levels of which remained stable (Fig. 7H,
blue dashed lines). Artificially increasing the dephosphorylation
rate (parameter k4; Fig. S3F) of MASTL tenfold allowed the
alternative model (Fig. 7G) to fit the experimental results for
MASTL and pThrCdk dephosphorylation (Fig. 7H, black lines).
However, when we tested the model using increasing activation of
PP1 (20–80%) instead of Cdk1 inhibition, there was no effect on
MASTL dephosphorylation or on pThrCdk substrates (Fig. 7I).
Therefore, even under these artificial conditions with highly
unstable phosphorylation of MASTL, PP1 is still absolutely
required to initiate the dephosphorylation of MASTL, ensuring
sufficient reactivation of PP2A, which then triggers the rapid
bistable mitotic exit switch.
DISCUSSION
Our results show that rapid dephosphorylation and deactivation of
MASTL is crucial for ensuring bistability during mitotic exit. We
propose that PP1 initiates the dephosphorylation of MASTL,
relieving the inhibition of PP2A, which then completes the full
deactivation of MASTL. The degradation of cyclin B, which begins
during metaphase (Gavet and Pines, 2010), initiates mitotic exit
because decreasing levels of cyclin B are likely to be sufficient to
relieve Cdk1 phosphorylation of Thr320 on PP1, allowing auto-
dephosphorylation and activation. Thus, we believe that our model
of bistable phosphatase reactivation works in combination with the
established bistable models of mitotic exit (López-Avilés et al.,
2009; Yang and Ferrell, 2013) and that this model accurately
represents the ultrasensitivity and irreversibility of the mitotic exit
switch.
Recent reports in fission yeast demonstrate that partial
reactivation of PP1 is required for subsequent PP2A-B55 and
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Fig. 7. PP2A-PP1 feedback is crucial for ultrasensitivity and bistability. (A) Effects of constitutively active MASTL on mitotic exit were simulated 50 times
(grey lines) using model a. (B,C) Using model a, the effect of PP1 inhibition on MASTL activity and pThrCdk substrates was simulated. Removal of the PP1 auto-
dephosphorylation loop (red line) completely abolished PP1 activity, disrupting bistability. Simulating partial inhibition of PP1 activity from 30–90% (blue and
green lines) by reducing PP1 autoactivation (see k2b Fig. S3F) resulted in a corresponding increase in the relative activity of MASTL and pThrCdk substrate
phosphorylation. (D,E) Similar to the models in A and B, except for the effects of PP2A inhibition on MASTL and pThrCdk substrate phosphorylation were
simulated by reducing k4 (see k4b; Fig. S3F) asmeasured byMASTL activity and pThrCdk substrates. (F) HeLa cells synchronised as per Fig. 1Awere treated for
1 h with increasing doses of the PP1 and PP2A inhibitor okadaic acid (OA) followed by 10 µM RO3306 (RO) for 30 min. Total cell lysates were analysed by
western blotting, and the levels of total PP1β, PP1 phosphorylated at Thr320 (pThr320-PP1), histone H3 phosphorylated at Thr3 (pThr3-H3) and pThrCdk
substrates, as well as the ratio of phosphorylated MASTL to total MASTL (pMASTL:MASTL), were quantified as a measure of mitotic exit and bistability. n=2
repeats. (G) Schematic of the final model c, which lacks the dephosphorylation of MASTL by PP1. (H) In the model a rev (dotted blue line), MASTL
dephosphorylation is not triggered and pThrCdk substrates are not dephosphorylated, unless PP2A feedback on MASTL is amplified tenfold (model c, bold red
line). (I) In model c, PP1 is activated to varying levels (black and blue lines) in place of Cdk1 inhibition, and the effect on MASTL activity is measured.
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PP2A-B56 (which comprises the PPP2R5A subunit) reactivation
during mitotic exit. Although the mitotic exit roles of PP1 and PP2A
in yeast and humans are not entirely conserved, this relay switch
appears to be maintained (Grallert et al., 2014). Furthermore, human
cells that have been depleted of PP2A-B55 delay during anaphase
rather than metaphase, with defects in post-mitotic spindle
breakdown and nuclear envelope reassembly (Schmitz et al.,
2010). If PP2A was responsible for the initial dephosphorylation
of MASTL, then an earlier metaphase arrest similar to that induced
by non-degradable cyclin B would be expected (Chang et al., 2003).
This interdependence of PP1 and PP2A for bistability in our model
also provides an explanation for previous reports that PP2A
dephosphorylates MASTL during mitotic exit (Hégarat et al.,
2014). In our model, PP2A is part of the ultrasensitive feedback
loop regulating PP1 and MASTL, and is needed for the
establishment of bistability. Consequently, partial inhibition of
PP2A is sufficient to disrupt PP1 reactivation and to block Cdk1
substrate dephosphorylation, thereby maintaining MASTL activity
and preventing mitotic exit. This accounts for the ability of
the phosphatase inhibitor okadaic acid to rescue MASTL
phosphorylation and to block mitotic exit at doses specific for
inhibition of PP2A. Additionally, our data show that >90% of PP1
needs to be inhibited to maintain complete phosphorylation of
MASTL and pThrCdk substrates. This is likely to explain why
complete depletion of PP1 prevents Cdk1 substrate
dephosphorylation and blocks mitotic exit in Xenopus extracts
(Wu et al., 2009). In contrast, inhibitors, such as tautomycin, are
unlikely to achieve this level of inhibition in human cells (Favre
et al., 1997), explaining why these experiments have failed
previously.
The final question remaining is how does PP1 initiate the
deactivation ofMASTL?We believe that PP1 dephosphorylates key
pThrCdk residues (Thr194, Thr207 and Thr741), initiating MASTL
deactivation. In support of this idea, mutating these sites to non-
phosphorylatable alanine residues reduces MASTL kinase activity
by up to 75%, triggering mitotic exit in Xenopus extracts (Blake-
Hodek et al., 2012). In addition, the amino acids surrounding
Thr207 match the TPG motif, which we have previously identified
as a highly unstable phosphorylation motif (McCloy et al., 2015).
Similarly, dephosphorylation at Thr194 during mitotic exit has also
been observed in a similar model of mitotic exit (Hégarat et al.,
2014). While preparing this manuscript, Heim et al. demonstrated in
Xenopus extracts that MASTL is also dephosphorylated by PP1.
Using several elegant experiments using a mutant (G41S), which
lacks auto-phosphorylation ability, they propose that the Ser883 site
(equivalent to Ser875 in human MASTL) is dephosphorylated by
PP1 (Heim et al., 2015). However, this mutant, which appears to act
as a dominant-negative protein (Vera et al., 2015), was only partially
phosphorylated during mitosis, and changes in phosphorylation on
Ser883 were not directly assessed. In contrast, we did not observe
any significant decrease in phosphorylation during mitotic exit
using a phosphorylation-specific antibody against human Ser875,
although PP1 could partially dephosphorylate this site in vitro. A
probable explanation for these differences is that PP1 can target
multiple sites on MASTL during early mitotic exit, providing
multiple different steady-states of MASTL (Thomson and
Gunawardena, 2009). These multiple sites could be targeted by
different PP1 isoforms, explaining the redundancy we observed
between the α and β isoforms. In addition, PP1γ, which we
also identified by performing mass spectrometry, might also be
involved in regulating MASTL. Consequently, future studies will
be needed to identify the specific phosphosites that are regulated by
the various PP1 and PP2A complexes to fully understand how these
phosphatases regulate MASTL and, ultimately, mitotic exit in
human cells.
In summary, we believe that our model provides an attractive
unifying theory where mitotic exit is triggered by an initial loss of
Cdk1 activity during late metaphase, allowing PP1 to begin the
dephosphorylation of MASTL, thereby releasing PP2A inhibition
and triggering the bistable switch that locks cells into the mitotic
exit pathway.
MATERIALS AND METHODS
Antibodies, chemicals and reagents
All antibodies used are listed in Table S7. Anti-MASTL rabbit polyclonal
and phospho-specific antibodies against Ser875 were generated as
previously described (Burgess et al., 2010; Vigneron et al., 2011). The
following chemicals were used: RO3306 (Axon MedChem), okadaic acid
sodium salt (A.G. Scientifix), nocodazole (Sigma-Aldrich), thymidine 2′-
deoxycytidine hydrate (Santa Cruz Biotechnology), protease inhibitor
cocktail (PIC) (Sigma-Aldrich), adenosine 5′-triphosphate (New England
Biolabs), (S)-MG132 (Cayman Chemicals), iodoacetamide (Sigma-
Aldrich) and TCEP-hydrochloride (ThermoFisher Scientific). PDP3
peptide (Reither et al., 2013) was synthesised using H-Rink Amide
ChemMatrix resin at a loading concentration of 0.52 mmol/g. Automated
and manual solid-phase peptide synthesis (SPPS), preparative and analytical
high-performance liquid chromatography and analytical LC-MS was
performed as described previously (Mitchell et al., 2015).
Cell culture and synchrony
All cell lines were validated with a >90% match at CellBank Australia or
American Type Culture Collection using short tandem repeat (STR)
profiling, and grown as previously described (Browne et al., 2013). HeLa
cells were synchronised as previously described (McCloy et al., 2015). For
mitotic exit synchrony, cells were treated with 10 μM RO3306.
siRNA design and transfection
The Promega T7 Ribomax Express RNAi system was used to produce
in vitro transcribed siRNAs against coding DNA sequence (CDS) target
sequences for MASTL (pool) 647 5′-GCTCGTTGGGATTTAACAC-3′,
1144 5′-GGACGCTCTTGTGTAAACC-3′, 1879 5′-GCTGTACAAGA-
GAGTAACC-3′; PP1α 180 5′-GATCTGCGGTGACATACAC-3′; PP1β
619 5′-GATCCAGATAAGGATGTGC-3′; PP2A catalytic subunit 784
5′-GCTCCAAACTATTGTTATC-3′; PP2A-B55 1297 5′-GTAGCTACT-
ACAAACAATC-3′; non-targeting control (NT) 5′-GGATTGTGCGGTC-
ATTAACTT-3′. Numbers in bold denote the starting nucleotide number of
the sequence within the CDS. Transfection of siRNAwas performed using
Lipofectamine 3000 reagent (Invitrogen), as per the manufacturer’s
instructions.
Western blot, immunoprecipitation and phosphatase and kinase
assays
Western blots were performed and quantified as previously described
(McCloy et al., 2014, 2015). For immunoprecipitations, protein A/G
magnetic beads (Pierce) were mixed with antibodies for 1.5–2 h at room
temperature before addition to lysates for 2 h at room temperature. For
in vitro phosphatase assays, HeLa cultures enriched for prometaphase cells
were treated with 100 nM okadaic acid for 1 h before harvesting. Cell pellets
were lysed in immunoprecipitation lysis buffer and MASTL was
immunoprecipitated (250 µg), and beads were washed three times with
immunoprecipitation lysis buffer, three times with 20 mM Tris-HCl (pH 8)
and resuspended in 50 µl of 1×NEBuffer for protein metallophosphatases
supplemented with 1 mM MnCl2. MASTL immunoprecipitates were then
treated without (Control) or with purified active PP1α (1 unit, NEB,
#P0754S), PP1β (0.1 µg, Abcam, #ab128551), or λ phosphatase (200 units,
NEB, #P0753S) for the indicated times at 30°C. Reactions were stopped
with 2× LDS-PAGE buffer with dithiothreitol and then boiled at 95°C
for 5 min. All samples were analysed by western blotting. Co-
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immunoprecipitations were performed identically, except without okadaic
acid. IgG- or primary-antibody-bound beads were mixed with lysates for
16–18 h at 4°C. In some cases, a second round of depletion was performed
for 2 h at room temperature. For MASTL kinase assays, mitotic exit and
interphase synchronised cells were treated as per the immunoprecipitation
protocol. Beads were washed in immunoprecipitation lysis buffer (without
NP-40), then kinase reaction buffer (KRB) (20 mMHEPES, 10 mMMgCl2,
0.1 mg ml−1 BSA, 1 mM DTT). Beads were resuspended in KRB plus
10 μg myelin basic protein and ATP to a final concentration of 400 μM,
incubated for 1 h at 37°C and analysed using Kinase GloMax Luminescence
kit (Promega) as per the manufacturer’s instructions. The values for
MASTL activity were normalized to the depletion efficiency of the total
MASTL immunoprecipitation.
Immunofluorescence and proximity ligation assays
Immunofluorescence (McCloy et al., 2014) and PLA assays (Rogers et al.,
2015a) were performed as previously described. All coverslips were
mounted in ProLong Gold (Life Technologies) and imaged on a Leica
DMI6000 SP8 confocal microscope with a 63×1.4 lens at 1024×1024
resolution powered by LAS AF v8.0. PLA dots were counted and annotated
using Imaris v8.1, as described previously (Burgess et al., 2012; Rogers
et al., 2015a). FIJI-ImageJ v1.50a and Adobe Photoshop CC 2015 were
used for image colouring and overlays.
SILAC labelling and mass spectrometry
HeLa cells were SILAC-labelled, as previously described (McCloy et al.,
2015), with immunoprecipitation and peptide purification described as per
Di Virgilio et al. (2013). Mass spectrometry, peptide analysis and
bioinformatics was performed as described previously (McCloy et al.,
2015; Rogers et al., 2015b).
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Montpellier, France; antibodies against full-length and phospho-S875 MASTL] for
their gifts.
Competing interests
The authors declare no competing or financial interests.
Author contributions
S.R. performed mitotic exit assays, immunoprecipitations, kinase assays, mass
spectrometry, immunofluorescence and PLA assays, and co-wrote the manuscript.
R.A.M., C.E.C., D.N.W., N.J.M. and R.J.P. assisted with generating data. B.L.P.,
R.J.D. and D.E.J. assisted with mass spectrometry. D.F., with D.R.C., constructed
and analysed the mathematical model. A.B. performed in vitro phosphatase assays,
performed data analysis, conceived, designed and wrote the manuscript.
Funding
A.B. and D.R.C. are Cancer Institute NSW Future Research Leader (CINSW FRL)
fellows. This work was supported by the CINSW FRL fellowship [ID number 10/FRL/
3-02]; The Patricia Helen Guest Fellowship; and the Petre Foundation. The funders
had no role in study design, data collection, analysis, decision to publish, or
preparation of the manuscript.
Supplementary information
Supplementary information available online at
http://jcs.biologists.org/lookup/suppl/doi:10.1242/jcs.179754/-/DC1
References
Bettencourt-Dias, M., Giet, R., Sinka, R., Mazumdar, A., Lock,W. G., Balloux, F.,
Zafiropoulos, P. J., Yamaguchi, S., Winter, S., Carthew, R. W. et al. (2004).
Genome-wide survey of protein kinases required for cell cycle progression.Nature
432, 980-987.
Blake-Hodek, K. A., Williams, B. C., Zhao, Y., Castilho, P. V., Chen, W., Mao, Y.,
Yamamoto, T. M. and Goldberg, M. L. (2012). Determinants for activation of the
atypical AGC kinase Greatwall during M phase entry. Mol. Cell. Biol. 32,
1337-1353.
Bouchoux, C. and Uhlmann, F. (2011). A quantitative model for ordered cdk
substrate dephosphorylation during mitotic exit. Cell 147, 803-814.
Browne, B. C., Hochgräfe, F., Wu, J., Millar, E. K. A., Barraclough, J., Stone, A.,
McCloy, R. A., Lee, C. S., Roberts, C., Ali, N. A. et al. (2013). Global
characterization of signalling networks associated with tamoxifen resistance in
breast cancer. FEBS J. 280, 5237-5257.
Burgess, A., Vigneron, S., Brioudes, E., Labbé, J.-C., Lorca, T. and Castro, A.
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(2009). Greatwall maintains mitosis through regulation of PP2A. EMBO J. 28,
2786-2793.
Vigneron, S., Gharbi-Ayachi, A., Raymond, A.-A., Burgess, A., Labbé, J.-C.,
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